Sign up USA
Proactive Investors - Run By Investors For Investors

Immuron set to commence Clostridium Difficile Infection study in Israel

The company’s IMM-529 is a naturally produced biological antibody product
Immuron set to commence Clostridium Difficile Infection study in Israel
The primary objective of the study is to assess IMM-529's safety and tolerability

Immuron (ASX:IMC, NASDAQ:IMRN) has been granted final approval to begin its first in-human, clinical study for the treatment of C.Difficile Infection (CDI).

CDI is a condition, acute especially in hospitals and in long-term in-patient care facilities due to bacterial toxin causing inflammation of the colon resulting in diarrhoea and in severe cases, death.

This is Immuron's first human clinical study using its IMM-529 product, following the results reported from a series of pre-clinical efficacy studies completed at Monash University.

READ: Immuron targets cash injection

IMM-529 is a naturally produced biological antibody product intended to prevent and treat CDI and designed to spare the gut microbiome from the effects of classic antibiotic treatments.

The new study is to be conducted at the Hadassah Medical Center in Jerusalem. Approval has been granted by the Hadassah Medical Center Ethics Committee and the Israeli Ministry of Health.

Immuron's clinical trial is designed to study a total of 60 patients diagnosed with CDI and have received standard of care antibiotic treatment.

Patients will be enrolled within three weeks of their diagnosis and will be randomised into either IMM-529 three times daily, or placebo, for 28 days.

The primary objective of the study is to assess IMM-529's safety and tolerability.

Immuron’s secondary endpoints are to evaluate the preliminary efficacy of IMM-529 as evaluated by the duration and severity of the symptoms and rate of disease recurrence.

View full IMC profile View Profile

Immuron Ltd Timeline

May 26 2016
February 04 2016

Related Articles

spreadsheet and calculator
January 25 2018
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business
picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use